Agreed. Crowdfunding of new product startups and crowdfunding of companies like Todos that already have the product and have successfully completed part of the clinical trials are marketed toward different investor bases.
Here's the link to the full article that was posted. If one reads the full article, it seems clear it is geared toward smaller startup projects, not a $1.9B independently-verified valuation of patent-protected IP. Definitely not the same.
Plus, I think they're only looking to raise $15-$20M if I remember Gerald's prior statements correctly. They're not going to get there with $88 average investment as stated in the article. The investors who will fund 3CL Pharma will range from venture capitalists to individual Todos investors who want a personal stake in 3CL Pharma outside of the part Todos owns.